Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
631
archived clinical trials in
Vaccines

MenB Vaccine: Implementation Via Information, Empowerment and Accessibility
Establishing and Evaluating a School and University Campus-Based Approach to Implementing Serogroup B Meningococcal (MenB) Disease Recommendations in Older Adolescents and Young Adults.
Status: Enrolling
Updated:  12/31/1969
UF Health Pediatrics - Gerold L. Schiebler CMS Center
mi
from
Gainesville, FL
MenB Vaccine: Implementation Via Information, Empowerment and Accessibility
Establishing and Evaluating a School and University Campus-Based Approach to Implementing Serogroup B Meningococcal (MenB) Disease Recommendations in Older Adolescents and Young Adults.
Status: Enrolling
Updated: 12/31/1969
UF Health Pediatrics - Gerold L. Schiebler CMS Center
mi
from
Gainesville, FL
Click here to add this to my saved trials
MenB Vaccine: Implementation Via Information, Empowerment and Accessibility
Establishing and Evaluating a School and University Campus-Based Approach to Implementing Serogroup B Meningococcal (MenB) Disease Recommendations in Older Adolescents and Young Adults.
Status: Enrolling
Updated:  12/31/1969
UF Health Pediatrics - Tower Square
mi
from
Gainesville, FL
MenB Vaccine: Implementation Via Information, Empowerment and Accessibility
Establishing and Evaluating a School and University Campus-Based Approach to Implementing Serogroup B Meningococcal (MenB) Disease Recommendations in Older Adolescents and Young Adults.
Status: Enrolling
Updated: 12/31/1969
UF Health Pediatrics - Tower Square
mi
from
Gainesville, FL
Click here to add this to my saved trials
MenB Vaccine: Implementation Via Information, Empowerment and Accessibility
Establishing and Evaluating a School and University Campus-Based Approach to Implementing Serogroup B Meningococcal (MenB) Disease Recommendations in Older Adolescents and Young Adults.
Status: Enrolling
Updated:  12/31/1969
UF Family Medicine - Eastside
mi
from
Gainesville, FL
MenB Vaccine: Implementation Via Information, Empowerment and Accessibility
Establishing and Evaluating a School and University Campus-Based Approach to Implementing Serogroup B Meningococcal (MenB) Disease Recommendations in Older Adolescents and Young Adults.
Status: Enrolling
Updated: 12/31/1969
UF Family Medicine - Eastside
mi
from
Gainesville, FL
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Birmingham, AL
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Anaheim, CA
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Paramount, CA
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Paramount, CA
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Sacramento, CA
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
San Jose, CA
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
San Jose, CA
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Nampa, ID
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Nampa, ID
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Newton, KA
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Newton, KA
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Topeka, KA
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Topeka, KA
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Cleveland, OH
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Erie, PA
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Erie, PA
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Cheraw, SC
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Cheraw, SC
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Layton, UT
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Layton, UT
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Murray, UT
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Murray, UT
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Orem, UT
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Orem, UT
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Provo, UT
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Provo, UT
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Syracuse, UT
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Syracuse, UT
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Marshfield, WI
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Marshfield, WI
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
North Charleston, SC
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
North Charleston, SC
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Kansas City, MO
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Kansas City, MO
Click here to add this to my saved trials
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
San Jose,
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
San Jose,
Click here to add this to my saved trials
Phase 1 Safety Study of Two Experimental HIV Vaccines
VRC 012: A Phase I Clinical Trial of the Safety and Immunogenicity of an HIV-1 Adenoviral Vector Serotype 35 Vaccine: Dose Escalation as a Single Agent and Prime-Boost Schedules With an HIV-1 Adenoviral Vector Serotype 5 Vaccine in Uninfected Adults
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Phase 1 Safety Study of Two Experimental HIV Vaccines
VRC 012: A Phase I Clinical Trial of the Safety and Immunogenicity of an HIV-1 Adenoviral Vector Serotype 35 Vaccine: Dose Escalation as a Single Agent and Prime-Boost Schedules With an HIV-1 Adenoviral Vector Serotype 5 Vaccine in Uninfected Adults
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
CU Center for Midwifery
mi
from
Aurora, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
CU Center for Midwifery
mi
from
Aurora, CO
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
CU Maternal and Fetal Medicine Clinic
mi
from
Aurora, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
CU Maternal and Fetal Medicine Clinic
mi
from
Aurora, CO
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
University Nurse Midwives
mi
from
Aurora, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
University Nurse Midwives
mi
from
Aurora, CO
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Boulder Women's Care
mi
from
Boulder, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Boulder Women's Care
mi
from
Boulder, CO
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
St. Joe's Midwives
mi
from
Denver, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
St. Joe's Midwives
mi
from
Denver, CO
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Partners in Women's Health at Rose
mi
from
Denver, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Partners in Women's Health at Rose
mi
from
Denver, CO
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Colorado Mountain Medical
mi
from
Edwards, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Colorado Mountain Medical
mi
from
Edwards, CO
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Bella Natural Women's Care
mi
from
Englewood, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Bella Natural Women's Care
mi
from
Englewood, CO
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Associates in Women's Health
mi
from
Golden, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Associates in Women's Health
mi
from
Golden, CO
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Women's Health Group Thornton
mi
from
Thornton, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Women's Health Group Thornton
mi
from
Thornton, CO
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Atlanta Women's Specialists
mi
from
Alpharetta, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Atlanta Women's Specialists
mi
from
Alpharetta, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Roswell Ob/Gyn
mi
from
Alpharetta, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Roswell Ob/Gyn
mi
from
Alpharetta, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Athens Midwifery
mi
from
Athens, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Athens Midwifery
mi
from
Athens, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Athens Ob-Gyn
mi
from
Athens, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Athens Ob-Gyn
mi
from
Athens, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Women's Healthcare Associates of Athens
mi
from
Athens, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Women's Healthcare Associates of Athens
mi
from
Athens, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Riverbend OB/GYN and Counseling
mi
from
Atlanta, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Riverbend OB/GYN and Counseling
mi
from
Atlanta, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Peachtree Women's Clinic
mi
from
Cumming, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Peachtree Women's Clinic
mi
from
Cumming, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Comprehensive Women's OB/GYN
mi
from
Duluth, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Comprehensive Women's OB/GYN
mi
from
Duluth, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Dunwoody Ob-Gyn
mi
from
Dunwoody, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Dunwoody Ob-Gyn
mi
from
Dunwoody, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Atlanta Gynecology & Obstetrics
mi
from
Lilburn, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Atlanta Gynecology & Obstetrics
mi
from
Lilburn, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Women's Medical Center
mi
from
Tyrone, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Women's Medical Center
mi
from
Tyrone, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
The Emory Clinic
mi
from
Atlanta, GA
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
The Emory Clinic
mi
from
Atlanta, GA
Click here to add this to my saved trials
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain OBGYN
mi
from
Denver, CO
P3+ Intervention Phase
A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain OBGYN
mi
from
Denver, CO
Click here to add this to my saved trials
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
A Phase 1, Randomized, Controlled, Observer-blind Study to Assess the Reactogenicity, Safety, and Immunogenicity of a Live Attenuated Universal Influenza Vaccine (cH8/1N1 LAIV) Administered as a Single Priming Dose Followed Three Months Later by a Single Booster Dose of an Inactivated Universal Influenza Vaccine (cH5/1N1 IIV) (Adjuvanted With AS03A or Unadjuvanted) in 18 Through 39 Year-old Healthy Subjects, Contrasted With a Two Dose Schedule of an Inactivated Universal Influenza Vaccine (cH8/1N1 IIV + AS03A Followed Three Months Later by cH5/1N1 IIV + AS03A)
Status: Enrolling
Updated:  12/31/1969
Duke University
mi
from
Durham, NC
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
A Phase 1, Randomized, Controlled, Observer-blind Study to Assess the Reactogenicity, Safety, and Immunogenicity of a Live Attenuated Universal Influenza Vaccine (cH8/1N1 LAIV) Administered as a Single Priming Dose Followed Three Months Later by a Single Booster Dose of an Inactivated Universal Influenza Vaccine (cH5/1N1 IIV) (Adjuvanted With AS03A or Unadjuvanted) in 18 Through 39 Year-old Healthy Subjects, Contrasted With a Two Dose Schedule of an Inactivated Universal Influenza Vaccine (cH8/1N1 IIV + AS03A Followed Three Months Later by cH5/1N1 IIV + AS03A)
Status: Enrolling
Updated: 12/31/1969
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
A Phase 1, Randomized, Controlled, Observer-blind Study to Assess the Reactogenicity, Safety, and Immunogenicity of a Live Attenuated Universal Influenza Vaccine (cH8/1N1 LAIV) Administered as a Single Priming Dose Followed Three Months Later by a Single Booster Dose of an Inactivated Universal Influenza Vaccine (cH5/1N1 IIV) (Adjuvanted With AS03A or Unadjuvanted) in 18 Through 39 Year-old Healthy Subjects, Contrasted With a Two Dose Schedule of an Inactivated Universal Influenza Vaccine (cH8/1N1 IIV + AS03A Followed Three Months Later by cH5/1N1 IIV + AS03A)
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
A Phase 1, Randomized, Controlled, Observer-blind Study to Assess the Reactogenicity, Safety, and Immunogenicity of a Live Attenuated Universal Influenza Vaccine (cH8/1N1 LAIV) Administered as a Single Priming Dose Followed Three Months Later by a Single Booster Dose of an Inactivated Universal Influenza Vaccine (cH5/1N1 IIV) (Adjuvanted With AS03A or Unadjuvanted) in 18 Through 39 Year-old Healthy Subjects, Contrasted With a Two Dose Schedule of an Inactivated Universal Influenza Vaccine (cH8/1N1 IIV + AS03A Followed Three Months Later by cH5/1N1 IIV + AS03A)
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated:  12/31/1969
Accel Research Sites
mi
from
Birmingham, AL
Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.
A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)
Status: Enrolling
Updated: 12/31/1969
Accel Research Sites
mi
from
Birmingham, AL
Click here to add this to my saved trials